Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04011826 · ClinicalTrials.gov registry record · NA
The Evaluation of a New Nasal Mask for the Treatment of Obstructive Sleep Apnea
A NA study, sponsored by Fisher and Paykel Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT04011826: Completed NA study, sponsored by Fisher and Paykel Healthcare.
NCT04011826 is a NA study that has completed, run by Fisher and Paykel Healthcare. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04011826, a NA study, has completed, sponsored by Fisher and Paykel Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of Obstructive Sleep Apnea (OSA) in the home environment.
Primary Outcome
Objective measure (determined from efficacy data recorded from the participants PAP/BPAP therapy device. Adequate therapy was evaluated by reviewing the Apnea Hypopnea Index (AHI) at baseline to intervention within each individual participants from their PAP therapy device reports. Maintenance of therapy was determined by evaluating the change in AHI. The below data demonstrates how many participants of the analyzed population demonstrated maintenance of therapy after using the new F\&P nasal m
Interventions
- DEVICE Device: Trial nasal mask (F&P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2020-08-30 |
| Phase | NA |
What the finished NCT04011826 record still lists
NCT04011826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Device: Trial nasal mask (F&P) is the first listed.
NCT04011826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04011826 about?
NCT04011826 is a clinical study titled "The Evaluation of a New Nasal Mask for the Treatment of Obstructive Sleep Apnea". This investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of Obstructive Sleep Apnea (OSA) in the home environment.
What is the current status of trial NCT04011826?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2019-08-05. Estimated completion is 2020-08-30.
What interventions are being tested in trial NCT04011826?
The interventions under investigation include: Device: Trial nasal mask (F&P) (DEVICE).
Who is sponsoring clinical trial NCT04011826?
This trial is sponsored by Fisher and Paykel Healthcare, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04011826's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI